A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 102-111

  Lopresti, Adrian L ^a   Maker, Garth L ^a   Hood, Sean D ^b   Drummond, Peter D ^a  

^a MURDOCH UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Biomarkers; Inflammation; Major depression; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FLUOXETINE; GAMMA INTERFERON; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INDOLEAMINE 2,3 DIOXYGENASE; INFLIXIMAB; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; KYNURENIC ACID; KYNURENINE; LIOTHYRONINE; MALONALDEHYDE; NEOPTERIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUPEROXIDE DISMUTASE; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

DIAGNOSTIC VALUE; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR DEPRESSION; OXIDATIVE STRESS; PREDICTIVE VALUE; RELAPSE; REMISSION; REVIEW; TREATMENT RESPONSE;

2,3-DINOR-5,6-DIHYDRO-15-F2T-ISOPROSTANE; 8-HYDROXY-2-DEOXYGUANOSINE; 8-OHDG; 8-OXO-7,8-DIHYDROGUANOSINE; 8-OXOGUO; BDNF; BIOMARKERS; BMI; BODY MASS INDEX; BRAIN-DERIVED NEUROTROPIC FACTOR; C-REACTIVE PROTEIN; COX; CRP; CYCLOOXYGENASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DSM; ECT; ELECTROCONVULSIVE THERAPY; ERYTHROCYTES SEDIMENTATION RATE; ESR; F2-ISOPM; GLUTATHIONE PEROXIDASE; GPX; GTP CYCLOHYDROLASE I; GTP-CH1; HIGH SENSITIVITY CRP; HS-CRP; IDO; IFN; IL; IL-2R; INDOLEAMINE 2,3 DIOXYGENASE; INFLAMMATION; INTERFERON; INTERLEUKIN; INTERLEUKIN-2 RECEPTOR; KYN; KYNA; KYNURENIC ACID; KYNURENINE; MAJOR DEPRESSION; MALONDIALDEHYDE; MDA; OXIDATIVE STRESS; RA; RBC; RED BLOOD CELL; RHEUMATOID ARTHRITIS; RIBONUCLEOSIDE; RNA; SEROTONIN REUPTAKE INHIBITOR; SOD; SSRI; SUPEROXIDE DISMUTASE; TNF; TRP; TRYCATS; TRYPTOPHAN; TRYPTOPHAN CATABOLITES ALONG THE IDO PATHWAY; TUMOUR NECROSIS FACTOR;

ANIMALS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFLAMMATION; OXIDATIVE STRESS;

EID: 84886259029     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.09.017     Document Type: Review

References (102)

1. Abdel-Nasser A.M., Abd El-Azim S., Taal E., El-Badawy S.A., Rasker J.J., Valkenburg H.A. Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 1998, 37(4):391-397.
2. Anderson D.N., Abou-Saleh M.T., Collins J., Hughes K., Cattell R.J., Hamon C.G., et al. Pterin metabolism in depression: an extension of the amine hypothesis and possible marker of response to ECT. Psychol Med 1992, 22(4):863-869.
3. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 64(1):43-51.
4. Biomarkers_Definitions_Working_Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95.
5. Boksa P. A way forward for research on biomarkers for psychiatric disorders. J Psychiatry Neurosci 2013, 38(2):75-77.
6. Bot M., Carney R.M., Freedland K.E., Rubin E.H., Rich M.W., Steinmeyer B.C., et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. J Psychosom Res 2011, 71(1):13-17.
7. Cabrera C., Artacho R., Gimenez R. Beneficial effects of green tea-a review. J Am Coll Nutr 2006, 25(2):79-99.
8. Celik C., Erdem M., Cayci T., Ozdemir B., Ozgur Akgul E., Kurt Y.G., et al. The association between serum levels of neopterin and number of depressive episodes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(2):372-375.
9. Chang H.H., Lee I.H., Gean P.W., Lee S.Y., Chi M.H., Yang Y.K., et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun 2012, 26(1):90-95.
10. Chavda N., Kantharia N.D., Jaykaran Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. J Pharmacol Pharmacother 2011, 2(1):11-16.
11. Choi J., Joseph L., Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 2013, 14(3):232-244.
12. Chung C.P., Schmidt D., Stein C.M., Morrow J.D., Salomon R.M. Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatry Res 2013, 206(2-3):213-216.
13. Codoner-Franch P., Navarro-Ruiz A., Fernandez-Ferri M., Arilla-Codoner A., Ballester-Asensio E., Valls-Belles V. A matter of fat: insulin resistance and oxidative stress. Pediatr Diabetes 2012, 13(5):392-399.
14. Copeland W.E., Shanahan L., Worthman C., Angold A., Costello E.J. Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis. Biol Psychiatry 2012, 71(1):15-21.
15. Dimopoulos N., Piperi C., Psarra V., Lea R.W., Kalofoutis A. Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression. Psychiatry Res 2008, 161(1):59-66.
16. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67(5):446-457.
17. Duivis H.E., Vogelzangs N., Kupper N., de Jonge P., Penninx B.W. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: Findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 2013, [Epub ahead of print]. 10.1016/j.psyneuen.2013.01.002.
18. Elovainio M., Aalto A.M., Kivimaki M., Pirkola S., Sundvall J., Lonnqvist J., et al. Depression and C-reactive protein: population-based Health 2000 Study. Psychosom Med 2009, 71(4):423-430.
19. Ford D.E., Erlinger T.P. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004, 164(9):1010-1014.
20. Forlenza M.J., Miller G.E. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom Med 2006, 68(1):1-7.
21. Gabbay V., Klein R.G., Katz Y., Mendoza S., Guttman L.E., Alonso C.M., et al. The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 2010, 51(8):935-943.
22. Galecki P., Szemraj J., Bienkiewicz M., Florkowski A., Galecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009, 61(3):436-447.
23. Galecki P., Szemraj J., Bienkiewicz M., Zboralski K., Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009, 24(4):277-286.
24. Gaskins A.J., Wilchesky M., Mumford S.L., Whitcomb B.W., Browne R.W., Wactawski-Wende J., et al. Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the BioCycle Study. Am J Epidemiol 2012, 175(5):423-431.
25. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36(12):2452-2459.
26. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007, 38(2):247-252.
27. Hestad K.A., Tonseth S., Stoen C.D., Ueland T., Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003, 19(4):183-188.
28. Hickman R.J., Khambaty T., Stewart J.C. C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. J Behav Med 2013, [Epub ahead of print]. 10.1007/s10865-013-9510-0.
29. Hiles S.A., Baker A.L., de Malmanche T., Attia J. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med 2012, 42(10):2015-2026.
30. Hiles S.A., Baker A.L., de Malmanche T., Attia J. A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 2012, 26(7):1180-1188.
31. Hilsenroth M.J., Baity M.W., Mooney M.A., Meyer G.J. DSM-IV Major Depressive Episode criteria: an evaluation of reliability and validity across three different rating methods. Int J Psychiatr Clin Pract 2004, 8(1):3-10.
32. Hoekstra R., van den Broek W.W., Fekkes D., Bruijn J.A., Mulder P.G., Pepplinkhuizen L. Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe, medication-resistant depression. Psychiatry Res 2001, 103(2-3):115-123.
33. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71(2):171-186.
34. Hrboticky N., Leiter L.A., Anderson G.H. Menstrual cycle effects on the metabolism of tryptophan loads. Am J Clin Nutr 1989, 50(1):46-52.
35. Hughes M.M., Carballedo A., McLoughlin D.M., Amico F., Harkin A., Frodl T., et al. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav Immun 2012, 26(6):979-987.
36. Iida T., Chikamura C., Inoue K., Ito Y., Ishikawa H., Teradaira R., et al. Association of STAI and SDS scores with 8-hydroxydeoxyguanosine and serotonin levels in young women with depressive symptoms. J Neuropsychiatry Clin Neurosci 2011, 23(1):E10.
37. Jorgensen A., Krogh J., Miskowiak K., Bolwig T.G., Kessing L.V., Fink-Jensen A., et al. Systemic oxidatively generated DNA/RNA damage in clinical depression: associations to symptom severity and response to electroconvulsive therapy. J Affect Disord 2013, 149(1-3):355-362.
38. Khanzode S.D., Dakhale G.N., Khanzode S.S., Saoji A., Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003, 8(6):365-370.
39. Khera A., McGuire D.K., Murphy S.A., Stanek H.G., Das S.R., Vongpatanasin W., et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005, 46(3):464-469.
40. Kluge W., Alsaif M., Guest P.C., Schwarz E., Bahn S. Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders. Expert Rev Mol Diagn 2011, 11(7):721-733.
41. Koc M., Karaarslan O., Abali G., Batur M.K. Variation in high-sensitivity C-reactive protein levels over 24hours in patients with stable coronary artery disease. Tex Heart Inst J 2010, 37(1):42-48.
42. Kodydkova J., Vavrova L., Zeman M., Jirak R., Macasek J., Stankova B., et al. Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 2009, 42(13-14):1368-1374.
43. Kotan V.O., Sarandol E., Kirhan E., Ozkaya G., Kirli S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(5):1284-1290.
44. Lakoski S.G., Cushman M., Criqui M., Rundek T., Blumenthal R.S., D'Agostino R.B., et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 2006, 152(3):593-598.
45. Lehtimaki K., Keranen T., Huuhka M., Palmio J., Hurme M., Leinonen E., et al. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J ECT 2008, 24(1):88-91.
46. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785.
47. Liu Y., Ho R.C., Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012, 139(3):230-239.
48. Liukkonen T., Silvennoinen-Kassinen S., Jokelainen J., Rasanen P., Leinonen M., Meyer-Rochow V.B., et al. The association between C-reactive protein levels and depression: results from the northern Finland 1966 birth cohort study. Biol Psychiatry 2006, 60(8):825-830.
49. Liukkonen T., Rasanen P., Jokelainen J., Leinonen M., Jarvelin M.R., Meyer-Rochow V.B., et al. The association between anxiety and C-reactive protein (CRP) levels: results from the Northern Finland 1966 birth cohort study. Eur Psychiatry 2011, 26(6):363-369.
50. Lopresti A.L., Hood S.D., Drummond P.D. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 2012, 26(12):1512-1524.
51. Luukinen H., Jokelainen J., Hedberg P. The relationships between high-sensitivity C-reactive protein and incident depressed mood among older adults. Scand J Clin Lab Invest 2010, 70(2):75-79.
52. Ma Y., Chiriboga D.E., Pagoto S.L., Rosal M.C., Li W., Merriam P.A., et al. Association between depression and C-reactive protein. Cardiol Res Pract 2010, 2011. [286509].
53. Mackay G.M., Forrest C.M., Christofides J., Bridel M.A., Mitchell S., Cowlard R., et al. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin Exp Pharmacol Physiol 2009, 36(4):425-435.
54. Maes M., Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012, 196(2-3):243-249.
55. Maes M., Scharpe S., Meltzer H.Y., Okayli G., Bosmans E., D'Hondt P., et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994, 54(2):143-160.
56. Maes M., Verkerkc R., Bonaccorsoa S., Ombeletd W., Bosmanse E., Scharpéc S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002, 71:1837-1848.
57. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett 2009, 30(6):715-722.
58. Maes M., Galecki P., Verkerk R., Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011, 32(3):264-273.
59. Maes M., Leonard B., Fernandez A., Kubera M., Nowak G., Veerhuis R., et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):659-663.
60. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol Lett 2011, 32(2):133-140.
61. Maes M., Mihaylova I., Kubera M., Ringel K. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry 2012, 36(1):169-175.
62. Maes M., Twisk F.N., Ringel K. Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother Psychosom 2012, 81(5):286-295.
63. Maes M., Kubera M., Leunis J.C., Berk M., Geffard M., Bosmans E. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 2013, 127(5):344-354.
64. Michalakeas C.A., Parissis J.T., Douzenis A., Nikolaou M., Varounis C., Andreadou I., et al. Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. J Card Fail 2011, 17(9):748-754.
65. Milaneschi Y., Cesari M., Simonsick E.M., Vogelzangs N., Kanaya A.M., Yaffe K., et al. Lipid peroxidation and depressed mood in community-dwelling older men and women. PLoS One 2013, 8(6):e65406.
66. Miller G.E., Cole S.W. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry 2012, 72(1):34-40.
67. Muller N., Myint A.M., Schwarz M.J. Inflammatory biomarkers and depression. Neurotox Res 2011, 19(2):308-318.
68. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007, 98(1-2):143-151.
69. Myint A.M., Bondy B., Baghai T.C., Eser D., Nothdurfter C., Schule C., et al. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain Behav Immun 2013, [Epub ahead of print]. 10.1016/j.bbi.2013.04.003.
70. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11(6):851-876.
71. O'Toole S.M., Chiappelli F., Rubin R.T. Plasma neopterin in major depression: relationship to basal and stimulated pituitary-adrenal cortical axis function. Psychiatry Res 1998, 79(1):21-29.
72. Ozcan M.E., Gulec M., Ozerol E., Polat R., Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19(2):89-95.
73. Pasco J.A., Nicholson G.C., Williams L.J., Jacka F.N., Henry M.J., Kotowicz M.A., et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 2010, 197(5):372-377.
74. Phillips J., Frances A., Cerullo M.A., Chardavoyne J., Decker H.S., First M.B., et al. The six most essential questions in psychiatric diagnosis: a pluralogue part 1: conceptual and definitional issues in psychiatric diagnosis. Philos Ethics Humanit Med 2012, 7:3.
75. Raison C.L., Miller A.H. Is depression an inflammatory disorder?. Curr Psychiatry Rep 2011, 13(6):467-475.
76. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70(1):31-41.
77. Rietveld A., Wiseman S. Antioxidant effects of tea: evidence from human clinical trials. J Nutr 2003, 133(10):3285S-3292S.
78. Rosello-Lleti E., de Burgos F.G., Morillas P., Cortes R., Martinez-Dolz L., Almenar L., et al. Impact of cardiovascular risk factors and inflammatory status on urinary 8-OHdG in essential hypertension. Am J Hypertens 2012, 25(2):236-242.
79. Rudnicka A.R., Rumley A., Lowe G.D., Strachan D.P. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 2007, 115(8):996-1003.
80. Rybka J., Kedziora-Kornatowska K., Banas-Lezanska P., Majsterek I., Carvalho L.A., Cattaneo A., et al. Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression. Free Radic Biol Med 2013, 63C:187-194.
81. Sarandol A., Sarandol E., Eker S.S., Erdinc S., Vatansever E., Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007, 22(2):67-73.
82. Schmidt H.D., Shelton R.C., Duman R.S. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology 2011, 36(12):2375-2394.
83. Scrandis D.A., Langenberg P., Tonelli L.H., Sheikh T.M., Manogura A.C., Alberico L.A., et al. Prepartum depressive symptoms correlate positively with C-reactive protein levels and negatively with tryptophan levels: a preliminary report. Int J Child Health Hum Dev 2008, 1(2):167-174.
84. Shanahan L., Copeland W.E., Worthman C.M., Erkanli A., Angold A., Costello E.J. Sex-differentiated changes in C-reactive protein from ages 9 to 21: the contributions of BMI and physical/sexual maturation. Psychoneuroendocrinology 2013, [Epub ahead of print]. 10.1016/j.psyneuen.2013.04.010.
85. Stefanescu C., Ciobica A. The relevance of oxidative stress status in first episode and recurrent depression. J Affect Disord 2012, 143(1-3):34-38.
86. Stein D.J., Phillips K.A., Bolton D., Fulford K.W., Sadler J.Z., Kendler K.S. What is a mental/psychiatric disorder? From DSM-IV to DSM-V. Psychol Med 2010, 40(11):1759-1765.
87. Sublette M.E., Galfalvy H.C., Fuchs D., Lapidus M., Grunebaum M.F., Oquendo M.A., et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011, 25(6):1272-1278.
88. Swardfager W., Herrmann N., Dowlati Y., Oh P.I., Kiss A., Walker S.E., et al. Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease. Psychoneuroendocrinology 2009, 34(10):1560-1566.
89. Theofylaktopoulou D., Midttun O., Ulvik A., Ueland P.M., Tell G.S., Vollset S.E., et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol 2013, 173(1):121-130.
90. Valkanova V., Ebmeier K.P., Allan C.L. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 2013, [Epub ahead of print]. 10.1016/j.jad.2013.06.004.
91. Vargas H.O., Nunes S.O., de Castro M.R., Vargas M.M., Barbosa D.S., Bortolasci C.C., et al. Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. Neurosci Lett 2013, 544:136-140.
92. Vogelzangs N., Duivis H.E., Beekman A.T., Kluft C., Neuteboom J., Hoogendijk W., et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2012, 2:e79.
93. Voinov B., Richie W.D., Bailey R.K. Depression and chronic diseases: it is time for a synergistic mental health and primary care approach. Prim Care Companion CNS Disord 2013, [Epub ahead of print]. 10.4088/PCC.12r01468.
94. Wander K., Brindle E., O'Connor K.A. C-reactive protein across the menstrual cycle. Am J Phys Anthropol 2008, 136(2):138-146.
95. Warden D., Rush A.J., Trivedi M.H., Fava M., Wisniewski S.R. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007, 9(6):449-459.
96. Wei Y.C., Zhou F.L., He D.L., Bai J.R., Ding H., Wang X.Y., et al. Oxidative stress in depressive patients with gastric adenocarcinoma. Int J Neuropsychopharmacol 2009, 12(8):1089-1096.
97. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005, 10(6):538-544.
98. Wium-Andersen M.K., Orsted D.D., Nielsen S.F., Nordestgaard B.G. Elevated C-reactive protein levels, psychological distress, and depression in 73 131 individuals. JAMA Psychiatry 2013, 70(2):176-184.
99. Woloshin S., Schwartz L.M. Distribution of C-reactive protein values in the United States. N Engl J Med 2005, 352(15):1611-1613.
100. Yager S., Forlenza M.J., Miller G.E. Depression and oxidative damage to lipids. Psychoneuroendocrinology 2010, 35(9):1356-1362.
101. Yi S., Nanri A., Matsushita Y., Kasai H., Kawai K., Mizoue T. Depressive symptoms and oxidative DNA damage in Japanese municipal employees. Psychiatry Res 2012, 200(2-3):318-322.
102. Zhang X.Y., Yao J.K. Oxidative stress and therapeutic implications in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013, [Epub ahead of print]. 10.1016/j.pnpbp.2013.03.003.